Table 3. HPV status, staging and treatment modes of the HNSCCs analyzed. Also, the TNM (tumor, neck metastasis, distant metastasis) classification is presented.
| High-risk/low-risk-HPV-positive (PCR) % (n) | |
|---|---|
| Lip (n=5) | 80%/80% (4/4) |
| Oral (n=24) | 52%/43% (12/10) |
| Oropharyngeal (n=19) | 47%/11% (9/2) |
| Hypopharyngeal (n=9) | 55%/22% (5/2) |
| Laryngeal (n=8) | 50%/0% (4/0) |
| Nasopharyngeal (n=8) | 38%/13% (3/1) |
| TNM | |
| T1 | 14 (19%) |
| T2 | 33 (46%) |
| T3 | 15 (21%) |
| T4 | 10 (14%) |
| N0 | 37 (54%) |
| N1 | 15 (22%) |
| N2 | 13 (19%) |
| N3 | 4 (6%) |
| M0 | 68 (99%) |
| M1 | 1 (1%) |
| Stage | |
| I | 6 (10%) |
| II | 18 (30%) |
| III | 12 (20%) |
| IVA | 19 (31%) |
| IVB | 5 (8%) |
| IVC | 1 (2%) |
| Grade | |
| 1 | 20 (38%) |
| 2 | 22 (42%) |
| 3 | 10 (19%) |
| Operative treatment | 45 (61%) |
| Chemoradiotherapy | 14 (19%) |
| Radiotherapy | 46 (63%) |